Lightcast

Market position

Positioned in the single-cell analysis tools market as a provider of function-focused measurement, contrasted in company and press statements with approaches that infer cell function rather than directly measuring it. Its investor base includes ARCH Venture Partners, M Ventures, Illumina Ventures, +ND Capital, Longwall Ventures and OMX Ventures.

Company materials emphasise massively parallel droplet handling that overcomes Poisson-limited loading, precise light-based control of droplet merging to create defined single cell-cell interactions, the ability to perform multiple sequential merges for step-wise assays, machine-learning-optimised droplet arraying with environmental control, digital traceability of individual droplets from load to dispense, and real-time export of live cells meeting user-defined criteria into standard well plates. Press coverage frames the differentiator as direct measurement of cellular function rather than inference.

Technology

The core technology uses optically controlled electrowetting-on-dielectric (oEWOD) — described as moving droplets with light and as integrating EWOD with microfluidics — to manipulate tens of thousands of picoliter-scale droplets on a chip. The workflow comprises droplet generation and loading from multiple inputs (four or eight specific inputs depending on configuration) optimised for fragile samples; droplet acquisition and filtering by size and content using 'light sprites'; machine-learning-optimised arraying where target droplets form the array and disqualified droplets are discarded within an environmentally controlled array; massively parallel merging of interdigitated sample droplets by field of view or across the whole chip, including multiple sequential merges; assaying via configurable brightfield and fluorescence imaging with a range of functional reporters processed in real time; and real-time dispensing of selected single or pooled cells into 96-well plates.

Go-to-market

Lightcast runs a 'Luminary' early-access programme for the Envisia platform, structured in stages: initial discussion of research needs, an optional internal seminar, scientific consultation and workplan drafting, assay development (performed at Lightcast or at the partner's site if the instrument is purchased), and support toward peer-reviewed publication. It works with pharmaceutical companies and academic institutions to validate performance, optimise workflows and broaden applications, supported by facilities in Cambridge, UK and Boston, US, and publishes posters, white papers and videos as scientific marketing collateral. Full commercial release of Envisia is planned for 2026.

Academic and translational researchers, pharmaceutical companies and biotech drug discovery groups working on antibody discovery, cell and immunotherapies, immunology and oncology.

Geography

Headquartered in Cambridge, UK, with a Boston Innovation Centre in the United States led by Head of the Innovation Centre Megan Gottlieb. Early-access partners include the Flemish Institute of Biotechnology (VIB) in Belgium.

History

Founded in 2019, Lightcast developed a technology that uses light to control picoliter-scale droplets for functional analysis of individual cells. Employee testimonials indicate team growth from at least 2021-2022 across software, chip fabrication, chemistry and biology functions. The company raised approximately £38 million (about $49 million at the time) in a Series B round in 2023, and a further $27 million from existing investors announced in April 2026. Over the year preceding the 2026 financing it expanded the Envisia early-access programme with pharmaceutical companies and academic institutions, and appointed Brad Crutchfield, former chief commercial officer of 10x Genomics, as an advisor to its board of directors.

Risks & controversies

The Envisia platform had not reached full commercial release as of the April 2026 financing, with commercialisation dependent on achieving technical, manufacturing and software readiness milestones; the 2026 round was raised from existing investors only. No controversies are reported in the sources.